Past Contracts

Previous years' contract solicitations can be viewed here: 

• Fiscal year 2020 Program Solicitation Public Health Service
• Fiscal year 2019 Program Soliciation Public Health Service
• Fiscal year 2018 Program Solicitation Public Health Service
• Fiscal year 2017 Program Solicitation Public Health Service
• Fiscal year 2016 Program Solicitation Public Health Service
• Fiscal Year 2015 SBIR Program Solicitation Public Health Service
• Fiscal Year 2014 SBIR Program Solicitaion Public Health Service
• Fiscal Year 2013 SBIR Program Solicitaion Public Health Service

PHS 2018 included 12 contract topics released by NCI:

• 370 - Targeted Therapy for Cancer- and Cancer Therapy-Related Cachexia
• 371 - Drugs to Exploit the Immune Response Generated by Radiation Therapy
• 372 - Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics
• 373 - Tools and Technologies for Monitoring RNA Modifications
• 374 - Novel Approaches for Local Delivery of Chemopreventive Agents
• 375 - Diagnostic Imaging for Cancer Immunotherapies
• 376 - Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and its Microenvironment
• 377 - Bridging the Guideline Implementation Gap: Clinical Decision-Support to Improve Cancer Symptom Management
• 378 - Mobile Application for Surveillance of Post-Radiation Therapy Health-Related Quality of Life
• 379 - Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients
• 380 - Computer Aided Decision Support for Radiation Oncology
• 381 - Development of Artificial Intelligence (AI) Tools to Understand and Duplicate Experts’ Radiation Therapy Planning for Prostate Cancer

  ** Q&A Amendment 1; Q&A Amendment 2; Q&A Amendment 3

PHS 2017 included 15 contract topics released by NCI:

• 355 - Cell and Animal-Based Models to Advance Cancer Health Disparity Research
• 356 - Tools and Technologies for Monitoring RNA
• 357 - Innovative Tools for Interrogating Tumor Microenvironment Dynamics
• 358 - Modulating the Microbiome to Improve Therapeutic Efficacy of Cancer Therapeutics
• 359 - Technologies for Differential Isolation of Exosomes and Oncosomes
• 360 - Manufacturing Innovation for the Production of Cell-Based Cancer Immunotherapies
• 361 - Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer
• 362 - Informatics Tools to Measure Cancer Care Coordination
• 363 - Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving
• 364 - Methods and Software for Integration of Cancer Metabolomic Data with Other –Omic and Imaging Data
• 365 - Imaging Informatics Tools and Resources for Clinical Cancer Research
• 366 - Clonogenic High-Throughput Assay for Screening Anti-Cancer Agents and Radiation Modulators
• 367 - Predictive Biomarkers to Improve Radiation Treatment
• 368 - Molecularly Targeted Radiation Therapy for Cancer Treatment
• 369 - Development of Pediatric Cancer Drug Delivery Devices

   **   Q&A Amendment 1, released on September 22, 2016. 

   *** Guide Notice (NOT-OD-16-123) for PHS 2017-1.

PHS2016 included 14 contract topics released by NCI:

• 341 - Development of Metabolomics Data Integration Methods and Software
• 342 - Validation of Mobile Technologies for Clinical Assessment, Monitoring, and Intervention
• 343 - An Electronic Platform for Cognitive Assessment in Cancer Patients
• 344 - Technologies for Differential Isolation of Exosomes and Oncosomes
• 345 - Predictive Biomarkers of Adverse Reactions to Radiation Treatment
• 346 - Molecularly Targeted Radiation Therapy For Cancer Treatment
• 347 - Signal Amplification to Enable Attomolar Quantitation in Slide-Based or ELISA Biomarker Immunoassays
• 348 - Identification and Capture of Enriched Tumor Zones with Preservation of Labile Biomarkers from Ultra-Cold Biopsies
• 349 - Proximity Slide Based Sandwich Immunoassay to Visualize Intramolecular Epitopes of Analytes in Tissue Sections
• 350 - Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer
• 351 - Modulating the Microbiome to Improve Efficacy of Cancer Therapeutics
• 352 - Cell and Animal-Based Models to Advance Cancer Health Disparity Research
• 353 - Cell-Free Nucleic Acid-Based Assay Development for Cancer Diagnosis
• 354 - Companion Diagnostics for Cancer Immunotherapies

PHS2015 included 7 contract topics released by NCI:

• 334 - Vacutubes to Preserve the Viability of Circulating Tumor Cells
• 335 - Development of Advanced Culture Systems for Expansion of Cancer Stem Cells
• 336 - Development of Novel Therapeutic Agents That Target Cancer Stem Cells
• 337 - Cell-Free Nucleic Acid-Based Assay Development for Cancer Diagnosis
• 338 - Predictive Biomarkers of Adverse Reactions to Radiation Treatment
• 339 - Systemic Targeted Radionuclide Therapy For Cancer Treatment
• 340 - Validation of Mobile Technologies for Clinical Assessment, Monitoring, and Intervention

PHS2014 included 8 contract topics released by NCI:

• 326 - Development of Novel Therapeutic Agents that Target Cancer Stem Cells
• 327 - Reformulation of Failed Chemotherapeutic Drugs
  • Click here for answers to frequently asked questions on contract topic 327 
• 328 - Validation of 3D Human Tissue Culture Systems that Mimic the Tumor Microenvironment
• 329 - Proteomic Analysis of Single Cells Isolated from Solid Tumors
• 330 - Generation of Site-Specific Phospho-Threonine Protein Standards for use in Cancer Assays
• 331 - Development of a Biosensor-Based Core Needle Tumor Biopsy Device
• 332 - Development of Radiation Modulators for Use During Radiotherapy
  • Click here for answers to frequently asked questions on contract topic 332
• 333 - Software Tools for the Development of Environmental Measures Related to Cancer Health Behaviors and Resources

PHS2013 included 13 contract topics released by NCI: